GEN Exclusives

More »

GEN News Highlights

More »
Dec 4, 2006

AVI BioPharma Recipient of $28M Biodefense Contract

  • AVI BioPharma executed a two-year $28-million research contract with the Defense Threat Reduction Agency (DTRA). The contract will fund AVI’s development of antisense therapeutics to treat the effects of Ebola, Marburg, and Junin hemorrhagic viruses, which are seen as biological warfare and bioterrorism agents.

    “This partnership with DTRA and the DoD serves as validation of AVI’s Neugene® antisense approach to gene silencing in general, as well as specific confirmation of AVI’s concept of rapid response therapeutics,” points out Alan P. Timmins, president and COO of AVI. “We believe that through this contract we will continue to demonstrate the safety and efficacy of our Neugene technology plus AVI’s ability to develop and produce countermeasures for a broad spectrum of existing and emerging biothreat agents.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?